Radiation Therapy in Oligometastatic Prostate Cancer.
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
15 11 2022
15 11 2022
Historique:
received:
10
05
2022
revised:
12
07
2022
accepted:
16
07
2022
pubmed:
26
7
2022
medline:
19
10
2022
entrez:
25
7
2022
Statut:
ppublish
Résumé
Prostate cancer ranges from localized, low risk to metastatic, morbid disease. Although radiation therapy (RT) is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of RT as an immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering RT in metastatic disease.
Identifiants
pubmed: 35878715
pii: S0360-3016(22)00732-5
doi: 10.1016/j.ijrobp.2022.07.014
pii:
doi:
Substances chimiques
Hormones
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
684-692Subventions
Organisme : NCI NIH HHS
ID : R01 CA105051
Pays : United States
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.